Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer
Status:
RECRUITING
Trial end date:
2026-02-24
Target enrollment:
Participant gender:
Summary
This study was a multicenter, randomized, open, single-dose, two-cycle, two-cross-dosing human bioequivalence trial designed to evaluate the bioequivalence of tested and reference preparations in breast cancer subjects.
Phase:
NA
Details
Lead Sponsor:
Sichuan Huiyu Pharmaceutical Co., Ltd
Collaborators:
Chongqing Traditional Chinese Medicine Hospital Qianfoshan Hospital The First Affiliated Hospital of Bengbu Medical University The First Affiliated Hospital of Henan University of Science and Technology The First Hospital of Jilin University